MISSISSAUGA, Ontario--(BUSINESS WIRE)--Apr. 18, 2018--
At the request of the Investment Industry Regulatory Organization of
Canada (“IIROC”), Covalon Technologies Ltd. (the "Company" or "Covalon")
(TSXV: COV; OTCQX: CVALF), wishes to confirm that the Company’s
management is unaware of any material change in the Company’s operations
that would account for the recent increase in market activity.
Covalon Technologies Ltd. researches, develops
and commercializes new healthcare technologies that help save lives
around the world. Covalon's patented technologies, products and services
address the advanced healthcare needs of medical device companies,
healthcare providers and individual consumers. Covalon's technologies
are used to prevent, detect and manage medical conditions in specialty
areas such as wound care, tissue repair, infection control, disease
management, medical device coatings and biocompatibility. To learn more
about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
This news release may contain assumptions, estimates, and other
forward-looking statements regarding future events. Such forward-looking
statements involve inherent risks and uncertainties and are subject to
factors, many of which are beyond the Company's control that may cause
actual results or performance to differ materially from those currently
anticipated in such statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180418006040/en/
Source: Covalon Technologies Ltd.
Covalon Technologies Ltd.
Brian Pedlar, 905.568.8400 x 233